WILMINGTON, Del.--(BUSINESS WIRE)--Combination of zibotentan with dapagliflozin showed statistically significant and clinically meaningful reductions in urinary albumin-to-creatinine ratio (UACR), ...
Hosted on MSN
AstraZeneca’s Phase III Study on Baxdrostat and Dapagliflozin: A Potential Game-Changer for CKD Treatment
AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback